S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end

ICON Public (ICLR) Stock Forecast & Price Target

$288.23
-3.59 (-1.23%)
(As of 04/19/2024 ET)

ICON Public Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 8 Analyst Ratings

Analysts' Consensus Price Target

$319.45
10.83% Upside
High Forecast$367.00
Average Forecast$319.45
Low Forecast$220.00
TypeCurrent Forecast
4/21/23 to 4/20/24
1 Month Ago
3/22/23 to 3/21/24
3 Months Ago
1/21/23 to 1/21/24
1 Year Ago
4/21/22 to 4/21/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
9 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$319.45$312.64$291.55$265.70
Predicted Upside10.83% Upside13.54% Upside15.48% Upside23.20% Upside
Get ICON Public Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

ICLR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ICLR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ICON Public Stock vs. The Competition

TypeICON PublicMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside10.83% Upside985.25% Upside11.92% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/4/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$345.00 ➝ $362.00+12.62%
4/4/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$346.00+7.76%
2/23/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$325.00 ➝ $350.00+12.37%
2/23/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$325.00 ➝ $355.00+14.38%
2/23/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$357.00 ➝ $367.00+17.11%
12/20/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$295.00 ➝ $330.00+18.21%
12/11/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$300.00 ➝ $315.00+15.61%
9/13/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$306.00+18.94%
7/14/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$280.00 ➝ $300.00+21.55%
5/1/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$245.00 ➝ $220.00+14.17%
4/28/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$271.00 ➝ $263.00+37.91%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:28 PM ET.

ICLR Price Target - Frequently Asked Questions

What is ICON Public's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for ICON Public stock is Buy based on the current 8 buy ratings for ICLR. The average twelve-month price prediction for ICON Public is $319.45 with a high price target of $367.00 and a low price target of $220.00. Learn more on ICLR's analyst rating history.

Do Wall Street analysts like ICON Public more than its competitors?

Analysts like ICON Public more than other Medical companies. The consensus rating for ICON Public is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how ICLR compares to other companies.

Does ICON Public's stock price have much upside?

According to analysts, ICON Public's stock has a predicted upside of 12.33% based on their 12-month stock forecasts.

What analysts cover ICON Public?

ICON Public has been rated by Barclays, Evercore ISI, Mizuho, Robert W. Baird, and Truist Financial in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ICLR) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners